Literature DB >> 30660354

Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry).

Angela Lowenstern1, Ann Marie Navar2, Shuang Li3, Salim S Virani4, Anne C Goldberg5, Michael J Louie6, L Veronica Lee7, Eric D Peterson2, Tracy Y Wang2.   

Abstract

Guideline implementation requires clinician knowledge but may be influenced by pre-existing beliefs and biases. We assessed the association of these clinician factors with lipid management following the release of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. In the PALM registry, 774 clinicians completed a survey to assess their knowledge of the 2013 American College of Cardiology/American Heart Association guidelines, belief in statin benefit, and statin safety concerns. The association of these factors with statin use, statin dosing, and low-density lipoprotein cholesterol (LDL-C) levels were assessed in the 6,839 patients treated by these clinicians between May and November 2015. Overall, 63.9% of clinicians responded to at least 3 out of 4 hypothetical scenarios in concordance with guideline recommendations (good tested knowledge), 88.4% reported belief in statin benefit, and 15.4% raised concerns about statin safety. Belief in statin benefit was more prevalent among cardiologists, who represented 48.8% of the clinicians surveyed, and concerns regarding statin safety were higher among noncardiologists and clinicians in an academic setting. Guideline knowledge was not associated with a difference in statin use (74.1% vs 73.8%, p = 0.84) and achievement of LDL-C level <100 mg/dl (54.7% vs 52.4%, p = 0.07). However, patients treated by clinicians who reported belief in statin benefit were more likely to receive guideline-recommended statin intensity (41.9% vs 36.9%, p = 0.03), whereas patients treated by clinicians expressing statin safety concerns were less likely receive statins of at least guideline-recommended intensity (36.8% vs 42.5%, p = 0.001) and to achieve an LDL-C <100 mg/dl (44.1% vs 56.1%, p <0.001); the latter persisted after multivariable adjustment (odds ratio 0.75, 95% confidence interval 0.63 to 0.89). In conclusion, clinician beliefs regarding benefits and risks of statins were significantly associated with guideline adherence and patients' achieved LDL-C levels, whereas clinician knowledge of guideline recommendations was not.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30660354      PMCID: PMC6526057          DOI: 10.1016/j.amjcard.2018.12.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  22 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.

Authors:  Joseph A Salami; Haider Warraich; Javier Valero-Elizondo; Erica S Spatz; Nihar R Desai; Jamal S Rana; Salim S Virani; Ron Blankstein; Amit Khera; Michael J Blaha; Roger S Blumenthal; Donald Lloyd-Jones; Khurram Nasir
Journal:  JAMA Cardiol       Date:  2017-01-01       Impact factor: 14.676

4.  Effect of two intensive statin regimens on progression of coronary disease.

Authors:  Stephen J Nicholls; Christie M Ballantyne; Philip J Barter; M John Chapman; Raimund M Erbel; Peter Libby; Joel S Raichlen; Kiyoko Uno; Marilyn Borgman; Kathy Wolski; Steven E Nissen
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

5.  Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.

Authors:  Kausik K Ray; Christopher P Cannon; Carolyn H McCabe; Richard Cairns; Andrew M Tonkin; Frank M Sacks; Graham Jackson; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2005-10-18       Impact factor: 24.094

6.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

Authors:  Paul S Jellinger; Yehuda Handelsman; Paul D Rosenblit; Zachary T Bloomgarden; Vivian A Fonseca; Alan J Garber; George Grunberger; Chris K Guerin; David S H Bell; Jeffrey I Mechanick; Rachel Pessah-Pollack; Kathleen Wyne; Donald Smith; Eliot A Brinton; Sergio Fazio; Michael Davidson
Journal:  Endocr Pract       Date:  2017-04       Impact factor: 3.443

7.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

8.  Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.

Authors:  Yashashwi Pokharel; Lynne Steinberg; Winston Chan; Julia M Akeroyd; Peter H Jones; Vijay Nambi; Khurram Nasir; Laura Petersen; Christie M Ballantyne; Salim S Virani
Journal:  Atherosclerosis       Date:  2016-01-06       Impact factor: 5.162

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry.

Authors:  Ann Marie Navar; Tracy Y Wang; Anne C Goldberg; Jennifer G Robinson; Veronique L Roger; Peter F Wilson; Salim S Virani; Joesph Elassal; L Veronica Lee; Laura E Webb; Eric Peterson
Journal:  Am Heart J       Date:  2015-08-07       Impact factor: 4.749

View more
  4 in total

1.  High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.

Authors:  Adam J Nelson; Kevin Haynes; Sonali Shambhu; Zubin Eapen; Mark J Cziraky; Michael G Nanna; Sara B Calvert; Kerrin Gallagher; Neha J Pagidipati; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2022-05-10       Impact factor: 27.203

2.  Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008-2019.

Authors:  Sara N Levintow; Stephanie R Reading; Sina Noshad; Sophie E Mayer; Catherine Wiener; Bassim Eledath; Jason Exter; M Alan Brookhart
Journal:  Clin Epidemiol       Date:  2022-06-01       Impact factor: 5.814

3.  Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry.

Authors:  Angela Lowenstern; Shuang Li; Salim S Virani; Ann Marie Navar; Zhuokai Li; Jennifer G Robinson; Veronique L Roger; Anne C Goldberg; Andrew Koren; Michael J Louie; Eric D Peterson; Tracy Y Wang
Journal:  Am Heart J       Date:  2020-04-30       Impact factor: 4.749

4.  Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States.

Authors:  Seth J Baum; Pallavi B Rane; Sasikiran Nunna; Mohdhar Habib; Kiran Philip; Kainan Sun; Xin Wang; Rolin L Wade
Journal:  Am J Prev Cardiol       Date:  2021-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.